Breaking News

Tweet TWEET

FDA Approval, Quarterly Reports, Event, and Licensing Agreement - Research Report on Novo Nordisk, DexCom, Theravance, PDL, and

  FDA Approval, Quarterly Reports, Event, and Licensing Agreement - Research
     Report on Novo Nordisk, DexCom, Theravance, PDL, and WuXi PharmaTech

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Novo
Nordisk A/S (NYSE: NVO), DexCom, Inc. (NASDAQ: DXCM), Theravance Inc. (NASDAQ:
THRX), PDL BioPharma, Inc. (NASDAQ: PDLI), and WuXi PharmaTech (Cayman) Inc.
(NYSE: WX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Novo Nordisk A/S Research Report

On November 1,2 013, Novo Nordisk A/S (Novo Nordisk) announced that the US
Food and Drug Administration (FDA) has approved the prefilled insulin pens
NovoRapid FlexTouch and Levemir FlexTouch. Novo Nordisk also reported that
Levemir FlexTouch has just been approved by the Canadian health authorities,
Health Canada. Mads Krogsgaard Thomsen, Executive Vice President and Chief
Science Officer of Novo Nordisk, stated, "Novo Nordisk is committed to
continuously developing new and better solutions within insulin delivery, and
this approval is an important milestone in the efforts to make the lives of
people with diabetes easier." The Full Research Report on Novo Nordisk A/S -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/fee1_NVO]

--

DexCom, Inc. Research Report

On November 6, 2013, DexCom, Inc. (DexCom) released its Q3 2013 results.
DexCom registered total revenues of $42.9 million, up approximately 85.7% YoY
in Q3 2013. The Company posted net loss of $6.0 million in Q3 2013, compared
to net loss of $17.3 million in Q3 2012. DexCom reported diluted loss per
share of $0.08 in Q3 2013, compared to diluted loss per share of $0.25 in Q3
2012. The Full Research Report on DexCom, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/d377_DXCM]

--

Theravance Inc. Research Report

On October 29, 2013, Theravance Inc. (Theravance) announced that Rick E.
Winningham, Theravance's CEO, will present during the 2013 Credit Suisse
Annual Health Care Conference on Wednesday, November 13, 2013, at 9:30 a.m.
MST. Theravance reported that the event will be held from November 11, 2013 to
November 14, 2013 at the Phoenician Hotel in Scottsdale, Arizona. The Company
informed that interested parties may access the live webcast through its
Investor Relations website. The Full Research Report on Theravance Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/fa70_THRX]

--

PDL BioPharma, Inc. Research Report

On November 6, 2013, PDL BioPharma, Inc. (PDL) released its Q3 2013 results.
PDL registered total revenues of $97.3 million in Q3 2013, up 14.2% YoY. The
Company posted net income of $56.2 million in Q3 2013, up 15.7% YoY. PDL
reported diluted EPS of $0.36 in Q3 2013, up 12.5% YoY. Commenting on the
results, John P. McLaughlin, President and CEO of PDL, said, "We are gratified
by the continued success of our asset acquisition strategy, including the four
additional transactions completed in the past month, and believe that-with ROI
at top-of-mind-we are continuing to add long term value for the company and
our stockholders." McLaughlin continued, "Our goal is to be the financial
partner of choice to leading life science companies and other institutions
seeking to access non-dilutive capital, and we are actively looking to expand
our portfolio. With the conclusion of the four recent transactions, PDL has
deployed $368 million in capital in 2013 and $496 million in total to acquire
new income generating assets to support our dividend payments." The Full
Research Report on PDL BioPharma, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[http://www.AnalystsCorner.com/r/full_research_report/066b_PDLI]

--

WuXi PharmaTech (Cayman) Inc. Research Report

On November 4, 2013, WuXi PharmaTech (Cayman) Inc. (WuXi PharmaTech) announced
a licensing agreement with Mayo Clinic's Center for Individualized Medicine to
expand WuXi PharmaTech's collection of patient-derived xenograft (PDX) mouse
models. According to the Company, it has been granted an exclusive license for
a panel of patient-derived xenograft models for prevailing cancers in Western
countries that have been developed in connection with the center's research
and patient care. Dr. Ge Li, Chairman and CEO of WuXi, commented, "This
agreement with the internationally renowned Mayo Clinic enables WuXi to
provide the global research community with a unique single resource that will
help advance cancer research through a more relevant and clinically directed
approach." Li added, "We look forward to working with world-class
organizations like Mayo Clinic to further strengthen our integrated,
open-access R&D services platform, which enables anyone and any company to
discover and develop new medicines for improved patient care." The Full
Research Report on WuXi PharmaTech (Cayman) Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/df7b_WX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America